Literature DB >> 24692176

Discovery, synthesis and characterization of a highly muscarinic acetylcholine receptor (mAChR)-selective M5-orthosteric antagonist, VU0488130 (ML381): a novel molecular probe.

Patrick R Gentry1, Masaya Kokubo, Thomas M Bridges, Hyekyung P Cho, Emery Smith, Peter Chase, Peter S Hodder, Thomas J Utley, Anuruddha Rajapakse, Frank Byers, Colleen M Niswender, Ryan D Morrison, J Scott Daniels, Michael R Wood, P Jeffrey Conn, Craig W Lindsley.   

Abstract

Of the five G-protein-coupled muscarinic acetylcholine receptors (mAChRs; M1-M5), M5 is the least explored and understood due to a lack of mAChR subtype-selective ligands. We recently performed a high-throughput functional screen and identified a number of weak antagonist hits that are selective for the M5 receptor. Here, we report an iterative parallel synthesis and detailed molecular pharmacologic profiling effort that led to the discovery of the first highly selective, central nervous system (CNS)-penetrant M5-orthosteric antagonist, with sub-micromolar potency (hM5 IC50=450 nM, hM5 Ki=340 nM, M1-M4 IC50>30 μM), enantiospecific inhibition, and an acceptable drug metabolism and pharmacokinetics (DMPK) profile for in vitro and electrophysiology studies. This compound will be a powerful tool and molecular probe for the further investigation into the role of M5 in addiction and other diseases.
© 2014 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  acetylcholine; antagonists; molecular probes; muscarinic acetylcholine receptors; orthosteric ligands

Mesh:

Substances:

Year:  2014        PMID: 24692176      PMCID: PMC4116439          DOI: 10.1002/cmdc.201402051

Source DB:  PubMed          Journal:  ChemMedChem        ISSN: 1860-7179            Impact factor:   3.466


  21 in total

1.  Allosteric modulation of seven transmembrane spanning receptors: theory, practice, and opportunities for central nervous system drug discovery.

Authors:  Bruce J Melancon; Corey R Hopkins; Michael R Wood; Kyle A Emmitte; Colleen M Niswender; Arthur Christopoulos; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2012-01-06       Impact factor: 7.446

Review 2.  Section I. The cholinergic system.

Authors:  John Smythies
Journal:  Int Rev Neurobiol       Date:  2005       Impact factor: 3.230

3.  Expression of muscarinic acetylcholine and dopamine receptor mRNAs in rat basal ganglia.

Authors:  D M Weiner; A I Levey; M R Brann
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

Review 4.  International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors.

Authors:  M P Caulfield; N J Birdsall
Journal:  Pharmacol Rev       Date:  1998-06       Impact factor: 25.468

5.  Brain-stimulation reward thresholds raised by an antisense oligonucleotide for the M5 muscarinic receptor infused near dopamine cells.

Authors:  J S Yeomans; J Takeuchi; M Baptista; D D Flynn; K Lepik; J Nobrega; J Fulton; M R Ralph
Journal:  J Neurosci       Date:  2000-12-01       Impact factor: 6.167

Review 6.  Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.

Authors:  Jürgen Wess; Richard M Eglen; Dinesh Gautam
Journal:  Nat Rev Drug Discov       Date:  2007-09       Impact factor: 84.694

7.  Discovery of (R)-(2-fluoro-4-((-4-methoxyphenyl)ethynyl)phenyl) (3-hydroxypiperidin-1-yl)methanone (ML337), an mGlu3 selective and CNS penetrant negative allosteric modulator (NAM).

Authors:  Cody J Wenthur; Ryan Morrison; Andrew S Felts; Katrina A Smith; Julie L Engers; Frank W Byers; J Scott Daniels; Kyle A Emmitte; P Jeffrey Conn; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-06-13       Impact factor: 7.446

Review 8.  Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.

Authors:  P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Trends Pharmacol Sci       Date:  2009-02-07       Impact factor: 14.819

9.  Discovery of the first M5-selective and CNS penetrant negative allosteric modulator (NAM) of a muscarinic acetylcholine receptor: (S)-9b-(4-chlorophenyl)-1-(3,4-difluorobenzoyl)-2,3-dihydro-1H-imidazo[2,1-a]isoindol-5(9bH)-one (ML375).

Authors:  Patrick R Gentry; Masaya Kokubo; Thomas M Bridges; Nathan R Kett; Joel M Harp; Hyekyung P Cho; Emery Smith; Peter Chase; Peter S Hodder; Colleen M Niswender; J Scott Daniels; P Jeffrey Conn; Michael R Wood; Craig W Lindsley
Journal:  J Med Chem       Date:  2013-11-13       Impact factor: 7.446

Review 10.  Muscarinic acetylcholine receptors as CNS drug targets.

Authors:  Christopher J Langmead; Jeannette Watson; Charlie Reavill
Journal:  Pharmacol Ther       Date:  2007-12-20       Impact factor: 12.310

View more
  12 in total

1.  Application of Parallel Multiparametric Cell-Based FLIPR Detection Assays for the Identification of Modulators of the Muscarinic Acetylcholine Receptor 4 (M4).

Authors:  Emery Smith; Peter Chase; Colleen M Niswender; Thomas J Utley; Douglas J Sheffler; Meredith J Noetzel; Atin Lamsal; Michael R Wood; P Jeffrey Conn; Craig W Lindsley; Franck Madoux; Mary Acosta; Louis Scampavia; Timothy Spicer; Peter Hodder
Journal:  J Biomol Screen       Date:  2015-04-15

2.  A Simple Representation of Three-Dimensional Molecular Structure.

Authors:  Seth D Axen; Xi-Ping Huang; Elena L Cáceres; Leo Gendelev; Bryan L Roth; Michael J Keiser
Journal:  J Med Chem       Date:  2017-08-08       Impact factor: 7.446

3.  Synthesis and evaluation of 4,6-disubstituted pyrimidines as CNS penetrant pan-muscarinic antagonists with a novel chemotype.

Authors:  Aaron M Bender; Rebecca L Weiner; Vincent B Luscombe; Hyekyung P Cho; Colleen M Niswender; Darren W Engers; Thomas M Bridges; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-04-04       Impact factor: 2.823

Review 4.  Current approaches for the discovery of drugs that deter substance and drug abuse.

Authors:  Adam Yasgar; Anton Simeonov
Journal:  Expert Opin Drug Discov       Date:  2014-09-24       Impact factor: 6.098

5.  Discovery and Optimization of Potent and CNS Penetrant M5-Preferring Positive Allosteric Modulators Derived from a Novel, Chiral N-(Indanyl)piperidine Amide Scaffold.

Authors:  Aaron M Bender; Hyekyung P Cho; Kellie D Nance; Kaelyn S Lingenfelter; Vincent B Luscombe; Patrick R Gentry; Karl Voigtritter; Alice E Berizzi; Patrick M Sexton; Christopher J Langmead; Arthur Christopoulos; Charles W Locuson; Thomas M Bridges; Sichen Chang; Jordan C O'Neill; Xiaoyan Zhan; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2018-04-26       Impact factor: 4.418

Review 6.  Molecular pharmacology of metabotropic receptors targeted by neuropsychiatric drugs.

Authors:  Bryan L Roth
Journal:  Nat Struct Mol Biol       Date:  2019-07-03       Impact factor: 15.369

7.  Further optimization of the M5 NAM MLPCN probe ML375: tactics and challenges.

Authors:  Haruto Kurata; Patrick R Gentry; Masaya Kokubo; Hyekyung P Cho; Thomas M Bridges; Colleen M Niswender; Frank W Byers; Michael R Wood; J Scott Daniels; P Jeffrey Conn; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2014-12-13       Impact factor: 2.823

8.  Continued optimization of the M5 NAM ML375: Discovery of VU6008667, an M5 NAM with high CNS penetration and a desired short half-life in rat for addiction studies.

Authors:  Kevin M McGowan; Kellie D Nance; Hykeyung P Cho; Thomas M Bridges; P Jeffrey Conn; Carrie K Jones; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2017-02-13       Impact factor: 2.823

9.  Ligand-based virtual screen for the discovery of novel M5 inhibitor chemotypes.

Authors:  Alexander R Geanes; Hykeyung P Cho; Kellie D Nance; Kevin M McGowan; P Jeffrey Conn; Carrie K Jones; Jens Meiler; Craig W Lindsley
Journal:  Bioorg Med Chem Lett       Date:  2016-07-30       Impact factor: 2.823

10.  Development of a highly potent, novel M5 positive allosteric modulator (PAM) demonstrating CNS exposure: 1-((1H-indazol-5-yl)sulfoneyl)-N-ethyl-N-(2-(trifluoromethyl)benzyl)piperidine-4-carboxamide (ML380).

Authors:  Patrick R Gentry; Masaya Kokubo; Thomas M Bridges; Meredith J Noetzel; Hyekyung P Cho; Atin Lamsal; Emery Smith; Peter Chase; Peter S Hodder; Colleen M Niswender; J Scott Daniels; P Jeffrey Conn; Craig W Lindsley; Michael R Wood
Journal:  J Med Chem       Date:  2014-09-03       Impact factor: 7.446

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.